Rare Disease Network for Myasthenia Gravis
Funded at George Washington University · NIH-11414937 · Data updated 2026-11-12
A nationwide effort to improve diagnosis, monitoring, and trial readiness for people with myasthenia gravis through biomarker work and better care tools.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | September 1, 2019 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $1,363,653 |
| NIH project number | 5U54NS115054-07 |
| Project ID | NIH-11414937 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals diagnosed with myasthenia gravis, including various MG subtypes (AChR antibody-positive, MuSK-positive, thymoma-associated, and seronegative forms).
✕Less likely to help
Patients not enrolled or who do not meet the study’s biomarker or monitoring criteria may not see direct benefits.
What this research studies
MGNet is a coordinated effort to better understand myasthenia gravis, a chronic autoimmune disease that affects how nerves communicate with muscles. The project aims to develop biomarkers, enhance early clinical trial readiness, and improve how patients are monitored during treatment. It will use electronic medical record-based tools to track patient data and identify signals that predict treatment responses. By studying different MG subtypes, the team hopes to tailor therapies and reduce adverse effects. This program spans multiple years and is led by George Washington University in collaboration with a network of researchers.
Why it matters
Potential benefit: If successful, patients could experience more personalized therapies, earlier access to effective treatments, and fewer treatment-related side effects.
How similar studies have gone: Previous MG research has shown biomarker discovery and trial-readiness concepts can improve outcomes, but gaps remain that this project aims to close.
Where this research is happening
-
George Washington University
Washington, United States Active
Researchers
- Principal investigator: Kaminski, Henry J — George Washington University
- Study coordinator: Kaminski, Henry J
Related research
Other NIH-funded projects on the same topics.
-
Understanding how autoimmunity causes myasthenia gravis
This project looks at why the immune system attacks the nerve-muscle connection in myasthenia gravis and how different patient groups are affected.
-
Biological age in myasthenia gravis: guiding who responds to treatment
A patient-friendly look at how a person’s biological age, not just their calendar age, might predict how MG patients respond to treatment and how treatments could even reduce biological aging.
-
CapTURE-MG: A patient-friendly MG data toolkit in a common EHR
A multi-site effort to use a streamlined MG toolkit inside the Epic EHR to collect consistent, real-world information about myasthenia gravis from routine care.
-
Understanding how autoimmune attacks cause myasthenia gravis
Researchers are studying how the immune system mistakenly targets the neuromuscular junction in myasthenia gravis to identify why the disease starts and how it progresses.
-
Mechanistically informed deep learning to study autoreactive B cells in Myasthenia Gravis
A study using advanced computer models to find hidden immune-cell signals in people with Myasthenia Gravis, including those who don’t yet show detectable antibodies.
-
Heterogeneity in autoimmune myasthenia gravis: classifying disease variants to guide personalized therapies
This research looks at different forms of myasthenia gravis to understand how unique immune factors drive the disease so doctors can tailor treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.